University of Nebraska Medical Center

Migraine Study in Children and Teens

teen girl sitting on bed looking unhappy

About the Study

What is the purpose of this study?

This study is investigating the study drug (rimegepant) to find out how well it works compared to the placebo. Rimegepant is considered investigational in this study because it has not been approved for use in children and teens for migraine. Placebo is a substance that looks like the study drug but has no active drug in it.

How long will this study last?

This study will last up to 19 weeks, and you will need to come to the study center up to four times over this period. Each office visit will generally last 1 to 2 hours.

Who can participate in this study?

  • To be eligible for this study, you must:
  • Be 12 to 17 years old
  • Have a history of migraine for 6 months or longer
  • Experience at least 1 migraine per month
  • Be able to understand the assent form and have parent(s)/caregiver(s) who can give informed consent

This is not a complete list of study requirements. The study doctor will review the full requirements for this study with you.


Click Here

Email for Information:

Principal Investigator:
Brad Brabec, MD
Child Health Research Institute, UNMC/Children's Hospital & Medical Center
985456 Nebraska Medical Center
Omaha, NE 68198-5456
UNMC IRB #0726-22-CB